Harbin Gloria Pharmaceuticals Co., Ltd

002437

CNE100000QG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-07-11			5-day change	1st Jan Change
3.130 ^CNY	-0.32%		+6.46%	+25.70%

Jun. 04	Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection	MT
May. 27	Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug	MT

Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection

Published on 06/04/2025 at 02:48

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Harbin Gloria Pharmaceuticals Co., Ltd

Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection	Jun. 04	MT
Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug	May. 27	MT
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 25	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director	Mar. 17	CI
Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024.	Mar. 14	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million.	Mar. 12	CI
Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024.	Mar. 10	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Announces Directorate Appointments	Feb. 07	CI
Declaration of Voting Results by Harbin Gloria Pharmaceuticals	Feb. 06	CI
Harbin Gloria Pharmaceuticals co Provides Information to the Shareholders	Jan. 26	CI
Shen Zhenyu Nominates Candidates to the Board of Harbin Gloria Pharmaceuticals	Jan. 26	CI
Harbin Gloria Pharmaceuticals Announces Results of the 2024 Third Extraordinary General Meeting	Nov. 22	CI
Shen Zhenyu Submits Proposal to Nominate Supervisors at Harbin Gloria Pharmaceuticals	24-10-28	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD announces an Equity Buyback for CNY 100 million worth of its shares.	24-10-22	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD authorizes a Buyback Plan.	24-10-20	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-23	CI
Chinese Securities Watchdog Warns Harbin Gloria Pharma Over Information Inaccuracies	24-08-19	MT
Harbin Gloria Pharmaceuticals' H1 Profit to Soar Up to 360%	24-07-04	MT
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-26	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-12	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD completed the acquisition of additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd.	23-10-27	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD agreed to acquire additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd. for CNY 35 million.	23-10-16	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD(XSEC:002437) added to S&P Global BMI Index	23-09-18	CI

Chart Harbin Gloria Pharmaceuticals Co., Ltd

Duration

Period

Chart Harbin Gloria Pharmaceuticals Co., Ltd

002437: Dynamic Chart

HARBIN GLORIA PHARMACEUTICALS Co., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The Company is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The Company distributes its products within domestic market and to overseas markets.

Employees

2,703

Sector

Pharmaceuticals

Calendar

Aug. 26 - Q2 2025 Earnings Release

More about the company